Clinical Trial Update: Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for Sunphenon EGCG in relapsing-remitting multiple sclerosis (SuniMS) completed phases 1 and 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Sunphenon Epigallocatechin-gallate (EGCg) (epigallocatechin-gallate)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Relapsing-remitting Multiple Sclerosis | Phase 1, Phase 2 | Status: COMPLETED